Autologous Hematopoietic Stem Cell Transplantation Promotes Connective Tissue Remodeling in Systemic Sclerosis Patients

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2022 Apr 30

PMID 35488348

Authors

Djulio C Zanin-Silva

Maynara Santana-Goncalves

Marianna Y Kawashima-Vasconcelos

Joao R Lima-Junior

Juliana B E Dias

Daniela A Moraes

Dimas T Covas

Kelen C R Malmegrim

Leandra Ramalho

Maria Carolina Oliveira

Affiliations

Soon will be listed here.

Abstract

Background: Autologous hematopoietic stem cell transplantation (AHSCT) treats patients with severe and progressive systemic sclerosis (SSc). However, basic mechanisms associated with the therapeutic efficacy of the procedure are not entirely understood. We aimed to evaluate how AHSCT affects skin fibrosis in SSc patients.

Methods: Clinical data, serum, and skin samples from 39 SSc patients who underwent AHSCT were retrospectively evaluated. Skin biopsies were analyzed by immunohistochemistry with anti-MMP-1, -MMP-2, -MMP-3, -MMP-9, -TIMP-1, -α-SMA, -TGF-β, and -NF-κB p65 antibodies, and stained with hematoxylin and eosin and picrosirius red to assess skin thickness and collagen density, respectively. Serum samples were evaluated by Multiplex Assay for COL1A1, COL4A1, FGF-1, MMP-1, MMP-3, MMP-12, MMP-13, PDGF-AA, PDGF-BB, S100A9, and TIMP-1 levels and compared to healthy controls.

Results: After AHSCT, SSc patients showed clinical improvement in skin involvement, assessed by modified Rodnan's skin score (mRSS). Histologically, collagen density and skin thickness decreased after AHSCT. Immunohistochemical analyses showed increased expression of MMP-2, MMP-3, MMP-9, and TIMP-1 after AHSCT, whereas expression of NF-κB p65 decreased. At baseline, serum levels of COL4A1 and S100A9 were higher than in healthy controls. Serum levels of S100A9 normalized after AHCST in SSc patients compared to controls. Serum levels of PDGF-AA, PDGF-BB, TIMP-1, and MMP-1 decreased, while COL1A1 increased after AHSCT in SSc patients. No changes were detected in MMP-3, MMP-12, MMP-13, and FGF-1 serum levels after AHSCT.

Conclusions: Our results suggest that the therapeutic effects of AHSCT on skin fibrosis are related to changes in molecules associated with connective tissue maintenance and inflammation in SSc.

Citing Articles

T-cell Recovery After Autologous Hematopoietic Stem Cell Transplantation in Autoimmune Diseases.

Santana-Goncalves M, De Santis P, Malmegrim K, Oliveira M Adv Exp Med Biol. 2025; 1471:301-323.

PMID: 40067593 DOI: 10.1007/978-3-031-77921-3_12.

Defining immune reset: achieving sustained remission in autoimmune diseases.

Junt T, Calzascia T, Traggiai E, da Costa A, Gergely P, Schett G Nat Rev Immunol. 2025; .

PMID: 40044810 DOI: 10.1038/s41577-025-01141-w.

Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment.

Chen L, Huang R, Huang C, Nong G, Mo Y, Ye L Front Med (Lausanne). 2025; 11:1530887.

PMID: 39882532 PMC: 11774712. DOI: 10.3389/fmed.2024.1530887.

Talabostat, fibroblast activation protein inhibitor, attenuates inflammation and fibrosis in systemic sclerosis.

Pashaei M, Farhadi E, Kavosi H, Madreseh E, Enayati S, Mahmoudi M Inflammopharmacology. 2024; 32(5):3181-3193.

PMID: 39167314 DOI: 10.1007/s10787-024-01536-6.

Association between Vitamin D Deficiency and Clinical Parameters in Men and Women Aged 50 Years or Older: A Cross-Sectional Cohort Study.

Lee J, Kim Y, Kim Y, Lee Y, Seo J Nutrients. 2023; 15(13).

PMID: 37447368 PMC: 10346261. DOI: 10.3390/nu15133043.

References

Chadli L, Sotthewes B, Li K, Andersen S, Cahir-McFarland E, Cheung M . Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients. Sci Rep. 2019; 9(1):4521. PMC: 6418101. DOI: 10.1038/s41598-019-41153-w. View

Chapman H . Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol. 2010; 73:413-35. DOI: 10.1146/annurev-physiol-012110-142225. View

Kroger N, Kvasnicka M, Thiele J . Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis. Fibrogenesis Tissue Repair. 2012; 5(Suppl 1):S25. PMC: 3368753. DOI: 10.1186/1755-1536-5-S1-S25. View

Malmegrim K, Rodrigues Lima-Junior J, Arruda L, Azevedo J, de Oliveira G, Oliveira M . Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: From Mechanistic Insights to Biomarkers. Front Immunol. 2018; 9:2602. PMC: 6250746. DOI: 10.3389/fimmu.2018.02602. View

Hinz B, Lagares D . Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases. Nat Rev Rheumatol. 2019; 16(1):11-31. PMC: 7913072. DOI: 10.1038/s41584-019-0324-5. View

Acharya N, Sharma S, Mishra D, Dhooria S, Dhir V, Jain S . Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int. 2020; 40(5):703-710. DOI: 10.1007/s00296-020-04565-w. View

Anderson J, Sale G, Appelbaum F, Chauncey T, Storb R . Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol. 1997; 98(4):1010-6. DOI: 10.1046/j.1365-2141.1997.3083125.x. View

Henrique-Neto A, Vasconcelos M, Dias J, de Moraes D, Goncalves M, Zanin-Silva D . Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience. Adv Rheumatol. 2021; 61(1):9. DOI: 10.1186/s42358-021-00166-8. View

Santana-Goncalves M, Zanin-Silva D, Henrique-Neto A, Moraes D, Kawashima-Vasconcelos M, Lima-Junior J . Autologous hematopoietic stem cell transplantation modifies specific aspects of systemic sclerosis-related microvasculopathy. Ther Adv Musculoskelet Dis. 2022; 14:1759720X221084845. PMC: 8966069. DOI: 10.1177/1759720X221084845. View

10.

Toubi E, Kessel A, Grushko G, Sabo E, Rozenbaum M, Rosner I . The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol. 2002; 20(2):221-4. View

11.

Peng W, Yan J, Wan Y, Wang B, Tao J, Yang G . Matrix metalloproteinases: a review of their structure and role in systemic sclerosis. J Clin Immunol. 2012; 32(6):1409-14. DOI: 10.1007/s10875-012-9735-7. View

12.

Abreu-Velez A, Howard M . Collagen IV in Normal Skin and in Pathological Processes. N Am J Med Sci. 2012; 4(1):1-8. PMC: 3289483. DOI: 10.4103/1947-2714.92892. View

13.

Kuroda K, Shinkai H . Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res. 1997; 289(10):567-72. DOI: 10.1007/s004030050241. View

14.

Manetti M, Romano E, Rosa I, Guiducci S, Bellando-Randone S, De Paulis A . Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Ann Rheum Dis. 2017; 76(5):924-934. DOI: 10.1136/annrheumdis-2016-210229. View

15.

Svegliati Baroni S, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M . Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006; 354(25):2667-76. DOI: 10.1056/NEJMoa052955. View

16.

Henes J, Oliveira M, Labopin M, Badoglio M, Scherer H, Papa N . Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. 2020; 106(2):375-383. PMC: 7849556. DOI: 10.3324/haematol.2019.230128. View

17.

Cantatore F, Maruotti N, Corrado A, Ribatti D . Angiogenesis Dysregulation in the Pathogenesis of Systemic Sclerosis. Biomed Res Int. 2017; 2017:5345673. PMC: 5534276. DOI: 10.1155/2017/5345673. View

18.

Aden N, Shiwen X, Aden D, Black C, Nuttall A, Denton C . Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford). 2008; 47(12):1754-60. DOI: 10.1093/rheumatology/ken370. View

19.

Hulmes D . Building collagen molecules, fibrils, and suprafibrillar structures. J Struct Biol. 2002; 137(1-2):2-10. DOI: 10.1006/jsbi.2002.4450. View

20.

Verrecchia F, Mauviel A . Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol. 2002; 118(2):211-5. DOI: 10.1046/j.1523-1747.2002.01641.x. View